{"id":348,"date":"2025-07-13T15:50:41","date_gmt":"2025-07-13T15:50:41","guid":{"rendered":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/?p=348"},"modified":"2025-07-13T15:50:41","modified_gmt":"2025-07-13T15:50:41","slug":"varmx-obtient-lautorisation-de-la-fda-pour-commencer-un-essai-de-phase-3-sur-vmx-c001","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/varmx-obtient-lautorisation-de-la-fda-pour-commencer-un-essai-de-phase-3-sur-vmx-c001\/","title":{"rendered":"VarmX obtient l’autorisation de la FDA pour commencer un essai de phase 3 sur VMX-C001"},"content":{"rendered":"

La soci\u00e9t\u00e9 de biotechnologie VarmX a re\u00e7u l’autorisation de la FDA am\u00e9ricaine pour d\u00e9buter un essai de phase 3 de son principal candidat, VMX-C001, chez des patients n\u00e9cessitant une chirurgie urgente tout en \u00e9tant sous anticoagulants oraux \u00e0 action directe contre le facteur Xa (FXa DOACs). Cette d\u00e9cision permet le lancement de l’essai mondial EquilibriX-S plus tard cette ann\u00e9e, couvrant plus de 20 pays. L’\u00e9tude \u00e9valuera l’efficacit\u00e9 de VMX-C001 \u00e0 restaurer la coagulation sanguine dans des contextes chirurgicaux d’urgence. VMX-C001 est une prot\u00e9ine humaine modifi\u00e9e du facteur X con\u00e7ue pour contourner les effets des FXa DOACs. Elle agit en r\u00e9tablissant rapidement et en toute s\u00e9curit\u00e9 le processus de coagulation, offrant des avantages tels qu’une posologie universelle, une facilit\u00e9 d’administration et une compatibilit\u00e9 avec les anticoagulants existants comme l’h\u00e9parine. Importamment, le traitement<\/a> ne augmente pas le risque thrombotique, une pr\u00e9occupation cl\u00e9 dans la gestion des sc\u00e9narios d’h\u00e9morragie d’urgence. VarmX voit cette th\u00e9rapie comme r\u00e9pondant \u00e0 un besoin m\u00e9dical non satisfait majeur, sans traitements approuv\u00e9s actuellement pour cette situation. D’ici 2030, on estime que 25 millions de patients en Am\u00e9rique et en Europe seront sous FXa DOACs pour des conditions \u00e0 long terme incluant la fibrillation auriculaire et la thrombose veineuse profonde. Chaque semaine, environ 25 000 de ces individus n\u00e9cessitent une chirurgie d’urgence ou souffrent d’h\u00e9morragies mettant leur vie en danger. John Glasspool, PDG de VarmX, a d\u00e9clar\u00e9 : \u00ab L’autorisation IND pour VMX-C001 marque une \u00e9tape majeure dans l’avancement de notre nouvel agent de d\u00e9rivation, con\u00e7u pour restaurer rapidement la coagulation afin de permettre une chirurgie urgente chez les patients sous anticoagulants oraux \u00e0 action directe contre le facteur Xa \u2013 un domaine sans traitements approuv\u00e9s aujourd’hui. Nous avan\u00e7ons maintenant avec nos plans pour initier notre essai de phase 3 plus tard cette ann\u00e9e. \u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"

La soci\u00e9t\u00e9 de biotechnologie VarmX a re\u00e7u l’autorisation de la FDA am\u00e9ricaine pour d\u00e9buter un essai de phase 3 de […]<\/p>\n","protected":false},"author":1,"featured_media":349,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=348"}],"version-history":[{"count":1,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/348\/revisions"}],"predecessor-version":[{"id":355,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/348\/revisions\/355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media\/349"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}